Sinopep-Allsino Faces Increased Leverage and Rising Costs Amid Market Challenges

Sinopep-Allsino Bio Pharmaceutical Co., Ltd., a midcap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in evaluation. This revision reflects a shift in the stock's technical score, indicating a change in market sentiment. Key financial metrics reveal that the company has faced challenges in its recent performance. The debt-equity ratio has reached a notable high of 60.35%, suggesting increased leverage, while the interest coverage ratio stands at a low of 879.16, indicating potential concerns regarding the company's ability to meet interest obligations. Additionally, raw material costs have risen by 6.78% year-over-year, which may impact profitability. Over the past year, Sinopep-Allsino has underperformed relative to the broader market, specifically the China Shanghai Composite, which has seen returns of 22.49%. In contrast, Sinopep-Allsino has recorded negative returns of -16.38%, highlighting the challenges the company faces in maintaining competitive performance. This evaluation adjustment underscores the evolving dynamics within the company and its market position. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.